Search results
21 hours ago · On Monday, Stifel raised the price target for Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) shares to €111.00 from €109.00, while reaffirming a Buy rating on the stock. The firm highlighted Sanofi as their top pick among large-cap pharmaceutical companies, despite its performance being one of the two ...
21 hours ago · The company's OX40 inhibitor is seen as a potential competitor to Dupixent, a leading treatment for atopic dermatitis marketed by Sanofi (EPA: SASY) (NASDAQ: SNY). According to Jefferies, Amgen's treatment could capture a $1-2 billion opportunity in the market due to its unique mechanism of action, which might offer more convenience and appeal, especially for patients who have previously been ...
4 hours ago · Shares of IDEAYA Biosciences, Inc. ( IDYA) gained nearly 20% on Monday morning after announcing positive interim phase 2 monotherapy expansion data for IDE397. IDYA is trading at $40.91, up $6.65 or 19.40%, on the Nasdaq. The stock began trading at $39.28 after closing Friday at $34.26. The stock has traded between $20.90 and $47.74 in the past ...
21 hours ago · (Bloomberg) -- Eli Lilly & Co. agreed to buy U.S. gut-drug maker Morphic Holding Inc. for about $3.2 billion, plowing some of the proceeds from obesity blockbuster Zepbound into its experimental ...
8 hours ago · There were 815 press releases posted in the last 24 hours and 398,616 in the last 365 days.
6 hours ago · “We are pleased to reintroduce Susvimo, a unique therapeutic approach shown to provide an effective alternative to regular eye injections by preserving vision with two refills per year in Phase III study patients with wet AMD,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development.
8 hours ago · Key Takeaways from the Fabry Disease Market Research Report • The total Fabry Disease market size in the 7MM is approximately USD 1,306 million in 2022 and is projected to increase during the ...
